http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 16:08:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EDAP+TMS+SA+++++++++++++++For%3A+Jun+01/26583551.html si-local-file:///var/storage/secattach/20260601/26583551.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EDAP+TMS+SA+++++++++++++++For%3A+Jun+01/26583551.html Mon, 01 Jun 2026 16:08:00 -0400 EDAP O.00325576 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EDAP+TMS+SA+++++++++++++++For%3A+Jun+01/26583551.html si-local-file:///var/storage/secattach/20260601/26583551.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EDAP+TMS+SA+++++++++++++++For%3A+Jun+01/26583551.html Mon, 01 Jun 2026 16:08:00 -0400 EDAP O.00325576 http://www.streetinsider.com/Corporate+News/EDAP+changes+name+to+FocalTherics%2C+shifts+focus+to+robotic+focal+therapy/26570770.html <p>EDAP TMS S.A. (NASDAQ: EDAP) announced it will operate under the new corporate name "FocalTherics" to reflect its focus on robotic focal therapy. The company will begin trading under the new ticker symbol "FOCL" at market open on June 1, 2026.</p> <p>The company plans to classify its Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution operating segments as discontinued operations beginning with second quarter 2026 financial results. CEO Ryan Rhodes said the new name derives from "Focal Therapy" and "Therapeutics" and aligns with the company's Focal One product brand.</p> <p>The ticker symbol change applies to the company's American Depositary Shares, with each representing http://www.streetinsider.com/Corporate+News/EDAP+changes+name+to+FocalTherics%2C+shifts+focus+to+robotic+focal+therapy/26570770.html Fri, 29 May 2026 07:30:18 -0400 EDAP O.00325576 http://www.streetinsider.com/Corporate+News/EDAP+changes+name+to+FocalTherics%2C+shifts+focus+to+robotic+focal+therapy/26570770.html <p>EDAP TMS S.A. (NASDAQ: EDAP) announced it will operate under the new corporate name "FocalTherics" to reflect its focus on robotic focal therapy. The company will begin trading under the new ticker symbol "FOCL" at market open on June 1, 2026.</p> <p>The company plans to classify its Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution operating segments as discontinued operations beginning with second quarter 2026 financial results. CEO Ryan Rhodes said the new name derives from "Focal Therapy" and "Therapeutics" and aligns with the company's Focal One product brand.</p> <p>The ticker symbol change applies to the company's American Depositary Shares, with each representing http://www.streetinsider.com/Corporate+News/EDAP+changes+name+to+FocalTherics%2C+shifts+focus+to+robotic+focal+therapy/26570770.html Fri, 29 May 2026 07:30:18 -0400 EDAP O.00325576 http://www.streetinsider.com/Corporate+News/EDAP+changes+name+to+FocalTherics%2C+shifts+focus+to+robotic+focal+therapy/26570769.html <p>EDAP TMS S.A. (NASDAQ: EDAP) announced it will operate under the new corporate name "FocalTherics" to reflect its focus on robotic focal therapy. The company will begin trading under the ticker symbol "FOCL" on June 1, 2026.</p> <p>The company plans to classify its Extracorporeal Shock Wave Lithotripsy and Distribution operating segments as discontinued operations beginning with second quarter 2026 financial results. The legal name will remain EDAP TMS S.A., with a formal name change requiring future shareholder approval.</p> <p>"FocalTherics is derived from the words 'Focal Therapy' and 'Therapeutics,'" said Ryan Rhodes, Chief Executive Officer. "This new name and identity reflects and reinforces http://www.streetinsider.com/Corporate+News/EDAP+changes+name+to+FocalTherics%2C+shifts+focus+to+robotic+focal+therapy/26570769.html Fri, 29 May 2026 07:30:16 -0400 EDAP http://www.streetinsider.com/Press+Releases/+++EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy++/26570756.html <p>, May 29, 2026 (GLOBE NEWSWIRE) -- <b>EDAP Announces Corporate Name Change to FocalTherics</b>^<b>™</b><b> to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy </b></p> <ul type="disc"><li style="margin-bottom:6pt;"><i>Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June 1, 2026</i></li><li style="margin-bottom:6pt;"><i>Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments </i>as Discontinued Operations Beginning with Second Quarter 2026 Financial Results</li><li style="margin-bottom:6pt;"><i>Investor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity</i><br /><br /></li></ul> <p>AUSTIN, Texas, May 29, 2026 - EDAP http://www.streetinsider.com/Press+Releases/+++EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy++/26570756.html Fri, 29 May 2026 07:30:00 -0400 EDAP http://www.streetinsider.com/Globe+Newswire/+++EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy++/26570756.html <p>, May 29, 2026 (GLOBE NEWSWIRE) -- <b>EDAP Announces Corporate Name Change to FocalTherics</b>^<b>™</b><b> to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy </b></p> <ul type="disc"><li style="margin-bottom:6pt;"><i>Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June 1, 2026</i></li><li style="margin-bottom:6pt;"><i>Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments </i>as Discontinued Operations Beginning with Second Quarter 2026 Financial Results</li><li style="margin-bottom:6pt;"><i>Investor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity</i><br /><br /></li></ul> <p>AUSTIN, Texas, May 29, 2026 - EDAP http://www.streetinsider.com/Globe+Newswire/+++EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy++/26570756.html Fri, 29 May 2026 07:30:00 -0400 EDAP http://www.streetinsider.com/Press+Releases/EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy/26570764.html <p>, May 29, 2026 (GLOBE NEWSWIRE) -- <b>EDAP Announces Corporate Name Change to FocalTherics</b><b>™</b><b> to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy </b></p> <ul type="disc"><li style="margin-bottom:6pt;"><i>Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June 1, 2026</i></li><li style="margin-bottom:6pt;"><i>Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments </i>as Discontinued Operations Beginning with Second Quarter 2026 Financial Results</li><li style="margin-bottom:6pt;"><i>Investor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity</i><br/><br/></li></ul> <p>AUSTIN, Texas, May 29, 2026 - EDAP TMS S.A. http://www.streetinsider.com/Press+Releases/EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy/26570764.html Fri, 29 May 2026 07:30:00 -0400 EDAP O.00325576 http://www.streetinsider.com/Press+Releases/EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy/26570764.html <p>, May 29, 2026 (GLOBE NEWSWIRE) -- <b>EDAP Announces Corporate Name Change to FocalTherics</b><b>™</b><b> to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy </b></p> <ul type="disc"><li style="margin-bottom:6pt;"><i>Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June 1, 2026</i></li><li style="margin-bottom:6pt;"><i>Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments </i>as Discontinued Operations Beginning with Second Quarter 2026 Financial Results</li><li style="margin-bottom:6pt;"><i>Investor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity</i><br/><br/></li></ul> <p>AUSTIN, Texas, May 29, 2026 - EDAP TMS S.A. http://www.streetinsider.com/Press+Releases/EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy/26570764.html Fri, 29 May 2026 07:30:00 -0400 EDAP O.00325576 http://www.streetinsider.com/Globe+Newswire/EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy/26570764.html <p>, May 29, 2026 (GLOBE NEWSWIRE) -- <b>EDAP Announces Corporate Name Change to FocalTherics</b><b>™</b><b> to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy </b></p> <ul type="disc"><li style="margin-bottom:6pt;"><i>Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June 1, 2026</i></li><li style="margin-bottom:6pt;"><i>Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments </i>as Discontinued Operations Beginning with Second Quarter 2026 Financial Results</li><li style="margin-bottom:6pt;"><i>Investor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity</i><br/><br/></li></ul> <p>AUSTIN, Texas, May 29, 2026 - EDAP TMS S.A. http://www.streetinsider.com/Globe+Newswire/EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy/26570764.html Fri, 29 May 2026 07:30:00 -0400 EDAP O.00325576 http://www.streetinsider.com/Globe+Newswire/EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy/26570764.html <p>, May 29, 2026 (GLOBE NEWSWIRE) -- <b>EDAP Announces Corporate Name Change to FocalTherics</b><b>™</b><b> to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy </b></p> <ul type="disc"><li style="margin-bottom:6pt;"><i>Company will Begin Trading Under New Ticker Symbol “FOCL” at Market Open on June 1, 2026</i></li><li style="margin-bottom:6pt;"><i>Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments </i>as Discontinued Operations Beginning with Second Quarter 2026 Financial Results</li><li style="margin-bottom:6pt;"><i>Investor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity</i><br/><br/></li></ul> <p>AUSTIN, Texas, May 29, 2026 - EDAP TMS S.A. http://www.streetinsider.com/Globe+Newswire/EDAP+Announces+Corporate+Name+Change+to+FocalTherics%E2%84%A2+to+Reflect+Exclusive+Focus+on+High-Growth+Robotic+Focal+Therapy/26570764.html Fri, 29 May 2026 07:30:00 -0400 EDAP O.00325576 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EDAP+TMS+SA+++++++++++++++For%3A+May+29/26570774.html si-local-file:///var/storage/secattach/20260529/26570774.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EDAP+TMS+SA+++++++++++++++For%3A+May+29/26570774.html Fri, 29 May 2026 07:30:00 -0400 EDAP O.00325576 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EDAP+TMS+SA+++++++++++++++For%3A+May+29/26570774.html si-local-file:///var/storage/secattach/20260529/26570774.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++EDAP+TMS+SA+++++++++++++++For%3A+May+29/26570774.html Fri, 29 May 2026 07:30:00 -0400 EDAP O.00325576 http://www.streetinsider.com/Press+Releases/EDAP+%7C+Focal+One+to+Present+at+Jefferies+2026+Global+Healthcare+Conference/26531454.html <p align="center">, May 21, 2026 (GLOBE NEWSWIRE) -- <strong>EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference</strong></p> <p align="justify"><i>Company to Present and Host 1x1 Investor Meetings on Thursday, June 4</i>^<i>th</i><i>, 2026</i></p> <p align="justify">AUSTIN, Texas, May 21^th, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Jefferies 2026 Global Healthcare Conference in New York.</p> <p><b>Date</b>: Thursday, June 4^th</p> http://www.streetinsider.com/Press+Releases/EDAP+%7C+Focal+One+to+Present+at+Jefferies+2026+Global+Healthcare+Conference/26531454.html Thu, 21 May 2026 07:30:00 -0400 EDAP http://www.streetinsider.com/Globe+Newswire/EDAP+%7C+Focal+One+to+Present+at+Jefferies+2026+Global+Healthcare+Conference/26531454.html <p align="center">, May 21, 2026 (GLOBE NEWSWIRE) -- <strong>EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference</strong></p> <p align="justify"><i>Company to Present and Host 1x1 Investor Meetings on Thursday, June 4</i>^<i>th</i><i>, 2026</i></p> <p align="justify">AUSTIN, Texas, May 21^th, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Jefferies 2026 Global Healthcare Conference in New York.</p> <p><b>Date</b>: Thursday, June 4^th</p> http://www.streetinsider.com/Globe+Newswire/EDAP+%7C+Focal+One+to+Present+at+Jefferies+2026+Global+Healthcare+Conference/26531454.html Thu, 21 May 2026 07:30:00 -0400 EDAP http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Corporate+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html <p>Telix Pharmaceuticals Limited (NASDAQ: TLX) announced it entered letters of intent with EDAP TMS S.A. (NASDAQ: EDAP) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN) to explore collaborations involving PSMA-PET imaging in prostate cancer treatment approaches.</p><p>The partnerships will investigate the use of Telix's PSMA-PET imaging agents Gozellix and Illuccix alongside robotic high-intensity focused ultrasound and transurethral ultrasound ablation technologies for treating localized prostate cancer. The collaborations aim to explore patient selection, treatment planning and post-treatment monitoring applications.</p><p>EDAP develops robotic energy-based therapies including the Focal One platform for prostate focal therapy. Profound Medical operates the TULSA-PRO platform, which enables MRI-guided prostate http://www.streetinsider.com/Hot+Corp.+News/Telix+partners+with+EDAP+and+Profound+on+prostate+imaging+tech/26498690.html Fri, 15 May 2026 06:31:09 -0400 EDAP PRN PROF TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html <ul type="disc"><li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.</li><li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.</li><li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies http://www.streetinsider.com/Press+Releases/Telix+Announces+Collaborations+to+Explore+PSMA-PET+Imaging+in+Emerging+Prostate+Cancer+Treatment+Approaches/26498657.html Fri, 15 May 2026 06:30:00 -0400 A.09642568 A.36051124 EDAP O.00325576 O.19076731 O.20371933 O.31276474 O.31712121 PRN PROF TLX TLX